Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes

Learn about integrating CAR T-cell therapy into the management of your patients with DLBCL, FL, MCL, and CLL/SLL to improve outcomes with an on-demand webcast, downloadable slideset, and expert commentary.

Share

Program Content

Activities

Integrating CAR-T Therapy in Lymphoma
Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2023

View Activity

Activities

CAR T Therapy in Lymphomas
Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 23, 2023

Expires: June 22, 2024

View Activity

Activities

FAQs: CAR T-Cell Tx in Lymphomas
Experts Answer Questions on Integrating CAR T-Cell Therapy Into the Management of DLBCL, FL, MCL, and CLL/SLL to Improve Outcomes
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 27, 2023

View Activity

Faculty

cover img faculity

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

cover img faculity

Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
UPMC Hillman Cancer Center,
University of Pittsburgh
Pittsburgh, Pennsylvania

cover img faculity

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb